Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans

Paul S. Aisen, Ronald Carl Petersen, Michael Donohue, Michael W. Weiner

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction This article reviews the current status of the Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project. Methods Clinical Core activities and plans were synthesized based on discussions among the Core leaders and external advisors. Results The longitudinal data in ADNI-2 provide natural history data on a clinical trials population and continue to inform refinement and standardization of assessments, models of trajectories, and clinical trial methods that have been extended into sporadic preclinical Alzheimer's disease (AD). Discussion Plans for the next phase of the ADNI project include maintaining longitudinal follow-up of the normal and mild cognitive impairment cohorts, augmenting specific clinical cohorts, and incorporating novel computerized cognitive assessments and patient-reported outcomes. A major hypothesis is that AD represents a gradually progressive disease that can be identified precisely in its long presymptomatic phase, during which intervention with potentially disease-modifying agents may be most useful.

Original languageEnglish (US)
Pages (from-to)734-739
Number of pages6
JournalAlzheimer's and Dementia
Volume11
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Neuroimaging
Alzheimer Disease
Clinical Trials
Natural History
Population

Keywords

  • Alzheimer's disease
  • Amyloid
  • Cognitive assessment

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Epidemiology
  • Health Policy

Cite this

Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core : Progress and plans. / Aisen, Paul S.; Petersen, Ronald Carl; Donohue, Michael; Weiner, Michael W.

In: Alzheimer's and Dementia, Vol. 11, No. 7, 01.07.2015, p. 734-739.

Research output: Contribution to journalArticle

Aisen, Paul S. ; Petersen, Ronald Carl ; Donohue, Michael ; Weiner, Michael W. / Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core : Progress and plans. In: Alzheimer's and Dementia. 2015 ; Vol. 11, No. 7. pp. 734-739.
@article{8f78e0a358124655aa92f3dc90f03133,
title = "Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans",
abstract = "Introduction This article reviews the current status of the Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project. Methods Clinical Core activities and plans were synthesized based on discussions among the Core leaders and external advisors. Results The longitudinal data in ADNI-2 provide natural history data on a clinical trials population and continue to inform refinement and standardization of assessments, models of trajectories, and clinical trial methods that have been extended into sporadic preclinical Alzheimer's disease (AD). Discussion Plans for the next phase of the ADNI project include maintaining longitudinal follow-up of the normal and mild cognitive impairment cohorts, augmenting specific clinical cohorts, and incorporating novel computerized cognitive assessments and patient-reported outcomes. A major hypothesis is that AD represents a gradually progressive disease that can be identified precisely in its long presymptomatic phase, during which intervention with potentially disease-modifying agents may be most useful.",
keywords = "Alzheimer's disease, Amyloid, Cognitive assessment",
author = "Aisen, {Paul S.} and Petersen, {Ronald Carl} and Michael Donohue and Weiner, {Michael W.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.jalz.2015.05.005",
language = "English (US)",
volume = "11",
pages = "734--739",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core

T2 - Progress and plans

AU - Aisen, Paul S.

AU - Petersen, Ronald Carl

AU - Donohue, Michael

AU - Weiner, Michael W.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Introduction This article reviews the current status of the Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project. Methods Clinical Core activities and plans were synthesized based on discussions among the Core leaders and external advisors. Results The longitudinal data in ADNI-2 provide natural history data on a clinical trials population and continue to inform refinement and standardization of assessments, models of trajectories, and clinical trial methods that have been extended into sporadic preclinical Alzheimer's disease (AD). Discussion Plans for the next phase of the ADNI project include maintaining longitudinal follow-up of the normal and mild cognitive impairment cohorts, augmenting specific clinical cohorts, and incorporating novel computerized cognitive assessments and patient-reported outcomes. A major hypothesis is that AD represents a gradually progressive disease that can be identified precisely in its long presymptomatic phase, during which intervention with potentially disease-modifying agents may be most useful.

AB - Introduction This article reviews the current status of the Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project. Methods Clinical Core activities and plans were synthesized based on discussions among the Core leaders and external advisors. Results The longitudinal data in ADNI-2 provide natural history data on a clinical trials population and continue to inform refinement and standardization of assessments, models of trajectories, and clinical trial methods that have been extended into sporadic preclinical Alzheimer's disease (AD). Discussion Plans for the next phase of the ADNI project include maintaining longitudinal follow-up of the normal and mild cognitive impairment cohorts, augmenting specific clinical cohorts, and incorporating novel computerized cognitive assessments and patient-reported outcomes. A major hypothesis is that AD represents a gradually progressive disease that can be identified precisely in its long presymptomatic phase, during which intervention with potentially disease-modifying agents may be most useful.

KW - Alzheimer's disease

KW - Amyloid

KW - Cognitive assessment

UR - http://www.scopus.com/inward/record.url?scp=84937571809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937571809&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2015.05.005

DO - 10.1016/j.jalz.2015.05.005

M3 - Article

C2 - 26194309

AN - SCOPUS:84937571809

VL - 11

SP - 734

EP - 739

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 7

ER -